Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

11,350articles mentioning institutions

22,378institution mentions

9,137distinct institutions extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted institutions

Showing 361–420 of 9,137, ordered by supporting articles. Choose a institution to see its evidence.

Dana Farber Cancer Institute5 ED5 Edinburgh University5 England5 GSK5 General Hospital5 Health Research Authority5 Health and Care Research Wales5 Heidelberg University Hospital5 Hospital Pharmacy Department5 Institute for Healthcare Improvement5 J Adv Nurs 20255 JAMA Psychiatry5 James Lind Alliance5 KU Leuven5 Leeds Teaching Hospitals5 Leiden University Medical Centre5 Level 1 trauma center5 MESH Registry5 NCT033015065 National Institute for Clinical Excellence5 Oncology5 Oslo University Hospital5 PAIS Index5 PsychINFO5 PubMed Central5 Radboud University Medical Center5 Royal College of Physicians5 Royal Free5 SNIS5 Simon Fraser University5 Sociological Abstracts5 South London and Maudsley NHS Foundation Trust5 St James’s Hospital5 Swedish CArdioPulmonary BioImage Study5 Synaptogenix5 Tikur Anbessa Specialized Hospital5 UN Digital Library5 University Medical Centre Ljubljana5 University of British Columbia5 University of Manitoba5 University of Melbourne5 University of Michigan5 World Health Organisation5 stroke centers5 Arm B4 ESMO4 Arm A4 Caris Life Sciences4 Stryker Neurovascular4 SIT4 ELSA4 HSS4 ESRA4 FDA-approved4 West China Hospital of Sichuan University4 Cass Review4 Cleveland Clinic4 European Kidney Function Consortium4 NHS Tayside4

View all 9,137 institutions on one page

Articles mentioning institutions

11,350 articles · page 212 of 946

P128 Treatment with elafibranor leads to stabilisation of PRO-C3, a marker of fibrosis, in patients with primary biliary cholangitis (PBC)

gutjnl · abstract · 2026-06-23 · 2 matching annotations

81.6%

N Eng J Med NCT04526665 PBC Elafibranor liver fibrosis ELA

…ful marker of disease progression.References Kowdley KV, et al. N Eng J Med. 2024;390:795–805.Kowdley, KV, et al. Hepatology. 2025;81:60.…

P14 Risk of post-ERCP pancreatitis following fully covered biliary metal stent placement: a multicentre retrospective analysis

gutjnl · abstract · 2026-06-23 · 2 matching annotations

93.6%

North Bristol NHS Trust Royal United Hospitals Bath NSAID PEP fcSEMS ERCP

… Bath (483 procedures, performed between 1.1.24 – 31.12.25) and North Bristol NHS Trust (400 procedures, performed between 1.1.19 – 31.10.23). Data was…

P158 Faecal immunochemical test surveillance after gastroenteropancreatic neuroendocrine tumour diagnosis: real-world incidence of metachronous colorectal cancer in two national registries

gutjnl · abstract · 2026-06-23 · 2 matching annotations

78.7%

NCRAS SEER colorectal cancer GEP-NET gastroenteropancreatic neuroendocrine tumours metachronous second primary malignancies

… the England National Cancer Registration and Analysis Service (NCRAS) 2012–2021 and the US Surveillance, Epidemiology, and End Resul…

P165 Pancyst watch audit

gutjnl · abstract · 2026-06-23 · 2 matching annotations

92.3%

PAH, Harlow pancreatic cancer Pancreatic cystic lesions

…month audit review demonstrates that pancreatic cyst pathway at PAH, Harlow effectively stratified patients by risk with appropriate escala…

P174 Impact of subcutaneous guselkumab induction therapy on molecular inflammation in ulcerative colitis (UC): results from the phase 3 ASTRO study

gutjnl · abstract · 2026-06-23 · 2 matching annotations

86.1%

ASTRO Guselkumab UC GUS QUASAR moderate to severe UC

…tes of administration in UC. Results from molecular analysis of ASTRO corroborate efficacy results for GUS SC induction in UC, with G…

P185 Impact of concomitant 5-aminosalicyclic acid therapy on upadacitinib efficacy and safety in ulcerative colitis: phase 3 clinical trials post-hoc analyses

gutjnl · abstract · 2026-06-23 · 2 matching annotations

85.3%

U-ACCOMPLISH U-ACHIEVE Upadacitinib UPA45 ulcerative colitis UPA30 5-ASA UPA15 UPA

…e 3 induction and maintenance trials (U-ACHIEVE [ NCT02819635], U-ACCOMPLISH [NCT03653026]). Only patients randomized to UPA for induction (…

P186 Remote, digitally enabled IBD monitoring at university hospitals Birmingham: fewer visits, better prioritisation

gutjnl · abstract · 2026-06-23 · 2 matching annotations

92.5%

University Hospitals Birmingham UHB Inflammatory Bowel Disease NHS Healthcare Innovation Consortium IBD

…ently receive care aligned to their disease activity.Methods At University Hospitals Birmingham (UHB), a digitally enabled IBD pathway underpinned by the Big P…

P190 The BSG IBD surveillance guideline endorsed advanced colorectal neoplasia risk assessment tool significantly reduces the need for future surveillance colonoscopy

gutjnl · abstract · 2026-06-23 · 2 matching annotations

95.7%

Oxford University Hospitals NHS Trust OUH NHS Trust colonic IBD multifocal LGD aCRN RAT

…rsonalised 5-year aCRN risk to inform surveillance interval. At Oxford University Hospitals NHS Trust, aCRN RAT has been incorporated into IBD surveillance assessmen…

P201 Predictors of early colectomy in ulcerative colitis: a real-world cohort study

gutjnl · abstract · 2026-06-23 · 2 matching annotations

77.5%

Mayo tertiary referral centre ulcerative colitis corticosteroids immunomodulators anti-TNF therapy UC

…was present in 66% of patients, and severe endoscopic activity (Mayo endoscopic score = 3) in 66%. Preoperative corticosteroids were…

P203 Bowel damage in a cohort of recently diagnosed crohn’s disease patients: results from the crohn´s disease cohort study

gutjnl · abstract · 2026-06-23 · 2 matching annotations

91.3%

CROCO 5ASA Crohn’s disease antiTNF BD ISS monotherapy

…agnosis) to characterise BD and disability trajectories.Methods CROCO enrolled 539 newly diagnosed CD patients across 19 centres (med…

P210 Guselkumab efficacy in moderate to severe ulcerative colitis by extent of disease and inflammatory burden in the QUASAR maintenance study

gutjnl · abstract · 2026-06-23 · 2 matching annotations

89.7%

Johnson & Johnson NCT04033445 Guselkumab GUS ulcerative colitis

…h GUS 200mg SC q4w compared with GUS 100mg SC q8w.Study support Johnson & Johnson.References Sachen KL, et al. Guselkumab binding to CD64+ IL-23–…

P226 Real-world evidence on effectiveness and safety of upadacitinib in moderate-to-severe ulcerative colitis patients from the PROFUNDUS study: UK interim analysis

gutjnl · abstract · 2026-06-23 · 2 matching annotations

83.6%

PROFUNDUS Upadacitinib UPA ulcerative colitis UC moderate-to-severe UC

…in the multi-country Prospective Real-World Study of UPA in UC (PROFUNDUS), to evaluate its effectiveness and safety in moderate-to-sever…